Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (293)

« Back to Publications

The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection.

Li S. et al, (2026), iScience, 29

Exploring the ethics of tuberculosis human challenge models.

Rohrig A. et al, (2026), Journal of medical ethics, 52, 251 - 260

Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.

Stewart I. et al, (2026), EBioMedicine, 124

Evaluation of 1st WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.

Khatri B. et al, (2025), Biologicals : journal of the International Association of Biological Standardization, 92

Acute Plasmodium yoelii 17XNL Infection During BCG Vaccination Limits T Cell Responses and Mycobacterial Growth Inhibition.

Tangie E. et al, (2025), Immunology, 176, 373 - 384

MetE: a promising protective antigen for tuberculosis vaccine development

Almujri SS. et al, (2025), Frontiers in Immunology, 16

Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States.

Chen C. et al, (2025), Chest, 168, 33 - 42

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response

Drennan PG. et al, (2025), The Lancet Microbe, 6, 101045 - 101045

Reducing inequalities through greater diversity in clinical trials – As important for medical devices as for drugs and therapeutics

Roope LSJ. et al, (2025), Contemporary Clinical Trials Communications, 45, 101467 - 101467

Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG

Marshall JL. et al, (2025), Nature Communications, 16

Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.

Siegal EZ. et al, (2025), NPJ vaccines, 10

Incidence of diabetes mellitus following hospitalisation for COVID ‐19 in the United Kingdom: A prospective observational study

Tyrer F. et al, (2025), Diabetes, Obesity and Metabolism, 27, 767 - 776

Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study

Gharibzadeh S. et al, (2025), eClinicalMedicine, 79, 103005 - 103005

Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.

Korompis M. et al, (2025), Scientific reports, 15

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.

De Voss CJ. et al, (2025), Frontiers in immunology, 16

Load More

1
2
3
4
5
6
7
...
»